Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Becocalcidiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 11/20 | 0.76 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Becocalcidiol SCHEMBL14489149 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9010345 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL14224828 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL9009884 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752369 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL859793 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL23752370 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL10820222 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL13666147 | 1.00 | VDR (0.76) | VDRCYP24A1 | |
| Becocalcidiol SCHEMBL798548 | 1.00 | VDR (0.76) | VDRCYP24A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | claimed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | claimed |
| EP-4065592-B1 | COCRYSTALS OF STEROID AND SECOSTEROID COMPOUNDS AND COMPOSITIONS COMPRISING THEM | CENTER FOR INTELLIGENT RES IN CRYSTAL ENGINEERING S L (ES) | 2024-01-10 | — | — | EP | claimed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | claimed |
| US-20230001012-A1 | COCRYSTALS OF STEROID AND SECOSTEROID COMPOUNDS AND COMPOSITIONS COMPRISING THEM | CENTER FOR INTELLIGENT RESEARCH IN CRYSTAL ENGINEERING, S.L. (ES) | 2023-01-05 | — | — | US | claimed |
| EP-4065592-A1 | COCRYSTALS OF STEROID AND SECOSTEROID COMPOUNDS AND COMPOSITIONS COMPRISING THEM | Center for Intelligent Research in Crystal Engineering, S.L. (ES) | 2022-10-05 | — | — | EP | claimed |
| CN-114846019-A | Co-crystals of steroids and secosteroids and compositions containing same | 晶体工程智能研究中心公司 | 2022-08-02 | — | — | CN | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | NOVARTIS AG (CH) | 2026-04-14 | — | — | US | disclosed |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | NOVARTIS AG (CH) | 2026-03-26 | — | — | US | disclosed |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2026-02-24 | — | — | US | disclosed |
| WO-2008089093-A2 | EFFICIENT PROCESSES FOR PREPARING STEROIDS AND VITAMIN D DERIVATIVES WITH THE UNNATURAL CONFIGURATION AT C20 (20 ALPHA-METHYL) FROM PREGNENOLONE | QUATRX PHARMACEUTICALS COMPANY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | QUATRX PHARMACEUTICALS CO. | 2008-07-17 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | DELUCA HECTOR F | 2008-06-19 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083842-A1 | PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES | IL17A, RAB7A, IL15 | VDR 2782/4885CYP24A1 3009/4885 |
| US-12599664-B2 | Pharmaceutical products and stable liquid compositions of IL-17 antibodies | IL17A, IL15, IL5 | VDR 1125/4885CYP24A1 763/4885 |
| US-20070105774-A1 | Administering an appropriate dosage schedule of a bone calcium resorption inhibitor like alendronate and a toxic dose of a vitamin D compounds like 1, alpha 25-dihydroxyvitamin D3 without developing hypercalcemia | CALCA, CALCRL, CYP24A1 | VDR 7/4885CYP24A1 3/4885 |
| US-12594332-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL23R | VDR 1638/4885CYP24A1 981/4885 |
| US-20080171728-A1 | Efficient Process for Preparing Steroids and Vitamin D Derivatives With the Unnatural Configuration at C20 (20 Alpha-Methyl) from Pregnenolone | CYP2R1, CYP24A1, VDR | VDR 3/4885CYP24A1 2/4885 |
| US-12559534-B2 | Modified IL-2 proteins, peg conjugates, and uses thereof | IL2, IL2RA, ILF2 | VDR 2204/4885CYP24A1 3025/4885 |
| US-12594331-B2 | Methods of treating psoriasis with secukinumab | IL17A, IL15, IL15RA | VDR 2047/4885CYP24A1 1236/4885 |
| US-20230001012-A1 | COCRYSTALS OF STEROID AND SECOSTEROID COMPOUNDS AND COMPOSITIONS COMPRISING THEM | HSD3B1, HSD3B2, NR3C2 | VDR 234/4885CYP24A1 35/4885 |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | VDR 671/4885CYP24A1 1973/4885 |
| US-20080146491-A1 | USE OF CALCITONIN AND CALCITONIN-LIKE PEPTIDES TO TREAT AND PREVENT MULTIPLE SCLEROSIS | CALCA, CALCB, CALCRL | VDR 5/4885CYP24A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.